WO2008057337A3 - Utilisation de composés organiques - Google Patents

Utilisation de composés organiques Download PDF

Info

Publication number
WO2008057337A3
WO2008057337A3 PCT/US2007/022902 US2007022902W WO2008057337A3 WO 2008057337 A3 WO2008057337 A3 WO 2008057337A3 US 2007022902 W US2007022902 W US 2007022902W WO 2008057337 A3 WO2008057337 A3 WO 2008057337A3
Authority
WO
WIPO (PCT)
Prior art keywords
edema
occurance
delaying
inhibitors
preventing
Prior art date
Application number
PCT/US2007/022902
Other languages
English (en)
Other versions
WO2008057337A2 (fr
Inventor
Boerk Balkan
David Grenville Holmes
Thomas Edward Hughes
Edwin Bernard Villhauer
Original Assignee
Novartis Ag
Boerk Balkan
David Grenville Holmes
Thomas Edward Hughes
Edwin Bernard Villhauer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Boerk Balkan, David Grenville Holmes, Thomas Edward Hughes, Edwin Bernard Villhauer filed Critical Novartis Ag
Priority to MX2009004627A priority Critical patent/MX2009004627A/es
Priority to CA002668162A priority patent/CA2668162A1/fr
Priority to EP07853026A priority patent/EP2079469A2/fr
Priority to AU2007318059A priority patent/AU2007318059A1/en
Priority to JP2009535293A priority patent/JP2010508348A/ja
Priority to BRPI0717874-3A priority patent/BRPI0717874A2/pt
Publication of WO2008057337A2 publication Critical patent/WO2008057337A2/fr
Publication of WO2008057337A3 publication Critical patent/WO2008057337A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

La présente invention concerne une méthode permettant de prévenir, de retarder la progression ou de réduire l'apparition d'un oedème, laquelle méthode consiste à administrer une quantité thérapeutiquement efficace d'un inhibiteur de la DPP-IV, ou d'un sel pharmaceutiquement acceptable de celui-ci, à un patient nécessitant un tel traitement.
PCT/US2007/022902 2006-11-01 2007-10-30 Utilisation de composés organiques WO2008057337A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2009004627A MX2009004627A (es) 2006-11-01 2007-10-30 Uso de inhibidores de dipeptidil-peptidasa iv para prevenir, demorar, o reducir la presentacion de edema.
CA002668162A CA2668162A1 (fr) 2006-11-01 2007-10-30 Utilisation de composes organiques
EP07853026A EP2079469A2 (fr) 2006-11-01 2007-10-30 Utilisation d'inhibiteurs de la dipeptidylpeptidase iv pour prévenir, retarder ou réduire l'occurence d'oedèmes
AU2007318059A AU2007318059A1 (en) 2006-11-01 2007-10-30 Use of Dipeptidyl peptidase IV inhibitors for preventing, delaying or reducing the occurance of edema
JP2009535293A JP2010508348A (ja) 2006-11-01 2007-10-30 浮腫の予防、遅延または軽減のためのジペプチジルペプチダーゼｉｖ阻害剤の使用
BRPI0717874-3A BRPI0717874A2 (pt) 2006-11-01 2007-10-30 Uso de compostos orgânicos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86381606P 2006-11-01 2006-11-01
US60/863,816 2006-11-01

Publications (2)

Publication Number Publication Date
WO2008057337A2 WO2008057337A2 (fr) 2008-05-15
WO2008057337A3 true WO2008057337A3 (fr) 2008-10-16

Family

ID=39365028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022902 WO2008057337A2 (fr) 2006-11-01 2007-10-30 Utilisation de composés organiques

Country Status (9)

Country Link
EP (1) EP2079469A2 (fr)
JP (1) JP2010508348A (fr)
KR (1) KR20090075747A (fr)
CN (1) CN101557811A (fr)
AU (1) AU2007318059A1 (fr)
BR (1) BRPI0717874A2 (fr)
CA (1) CA2668162A1 (fr)
MX (1) MX2009004627A (fr)
WO (1) WO2008057337A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057200A2 (fr) * 2002-01-11 2003-07-17 Novo Nordisk A/S Methode et composition permettant de traiter le diabete, l'hypertension, l'insuffisance cardiaque chronique et les troubles de retention de fluide
US20050021092A1 (en) * 2003-06-09 2005-01-27 Yun Anthony Joonkyoo Treatment of conditions through modulation of the autonomic nervous system
WO2006047248A1 (fr) * 2004-10-25 2006-05-04 Novartis Ag Combinaison d'inhibiteur de la dpp-iv, d'antidiabetique ppar et de metformine
WO2007035665A1 (fr) * 2005-09-20 2007-03-29 Novartis Ag Utilisation d’un inhibiteur de la ddp-iv en vue de réduire les crises d’hypoglycémie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057200A2 (fr) * 2002-01-11 2003-07-17 Novo Nordisk A/S Methode et composition permettant de traiter le diabete, l'hypertension, l'insuffisance cardiaque chronique et les troubles de retention de fluide
US20050021092A1 (en) * 2003-06-09 2005-01-27 Yun Anthony Joonkyoo Treatment of conditions through modulation of the autonomic nervous system
WO2006047248A1 (fr) * 2004-10-25 2006-05-04 Novartis Ag Combinaison d'inhibiteur de la dpp-iv, d'antidiabetique ppar et de metformine
WO2007035665A1 (fr) * 2005-09-20 2007-03-29 Novartis Ag Utilisation d’un inhibiteur de la ddp-iv en vue de réduire les crises d’hypoglycémie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AHREN B ET AL: "Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 27, no. 12, 1 December 2004 (2004-12-01), pages 2874 - 2880, XP002412952, ISSN: 0149-5992 *
PANINA G: "The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.", DIABETES, OBESITY & METABOLISM SEP 2007, vol. 9 Suppl 1, September 2007 (2007-09-01), pages 32 - 39, XP002480989, ISSN: 1462-8902 *
ROY ET AL: "Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: Preclinical efficacy and safety in db/db mice", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 81, no. 1, 12 June 2007 (2007-06-12), pages 72 - 79, XP022114319, ISSN: 0024-3205 *
SITAGLIPTIN STUDY 019 GROUP ROSENSTOCK ET AL: "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 28, no. 10, 15 November 2006 (2006-11-15), pages 1556 - 1568, XP005793112, ISSN: 0149-2918 *

Also Published As

Publication number Publication date
EP2079469A2 (fr) 2009-07-22
MX2009004627A (es) 2009-05-22
BRPI0717874A2 (pt) 2013-10-29
CA2668162A1 (fr) 2008-05-15
JP2010508348A (ja) 2010-03-18
CN101557811A (zh) 2009-10-14
WO2008057337A2 (fr) 2008-05-15
AU2007318059A1 (en) 2008-05-15
KR20090075747A (ko) 2009-07-08

Similar Documents

Publication Publication Date Title
WO2007149797A3 (fr) Utilisation de composés organiques
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
HUS1400008I1 (hu) Dipeptidil peptidáz inhibitorok adagolása
WO2008124085A3 (fr) Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
MX2007004020A (es) Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.
WO2011055944A3 (fr) Procédés pour traiter un syndrome de fibromyalgie
WO2008127975A3 (fr) Utilisation d'un inhibiteur de tnfa et d'une anti-histamine pour traiter la rhinite allergique et la conjonctivite allergique
MX2009004984A (es) Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
MY146830A (en) Combination of organic compounds
WO2005079795A3 (fr) Utilisation de composes organiques
WO2007100895A3 (fr) Traitement anticancéreux utilisant des inhibiteurs de gamma-sécrétases
WO2005072713A3 (fr) Inhibiteurs de la cholinesterase pour traiter l'inflammation
WO2007056324A3 (fr) Combinaison de composes organiques pour le traitement des maladies cardiovasculaires
IL200653A0 (en) Weekly administration of dipeptidyl peptidase inhibitors
WO2008109681A3 (fr) Procédés et intermédiaires pour la synthèse d'inhibiteurs sélectifs de dpp-iv
WO2009043170A8 (fr) Traitement de dissection, d'anévrisme et d'athérosclérose au moyen d'inhibiteurs de granzyme b
WO2007044325A3 (fr) Inhibiteurs de l'interaction du domaine apoe4 et methodes d'utilisation
WO2008031835A3 (fr) Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf
WO2009155070A3 (fr) Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques
WO2007149543A3 (fr) Traitement de cicatrices à l'aide d'inhibiteurs de protéine phosphatase
TNSN08383A1 (en) Renin inhibitors for the treatment of hypertension
WO2008057337A3 (fr) Utilisation de composés organiques
WO2007136615A3 (fr) Thérapie anticancéreuse combinée
WO2007097980A3 (fr) Inhibiteur de l'ubiquitine/protéasome pour le traitement de l'atrophie musculaire spinale
WO2006133231A3 (fr) Traitement de maladies neurodegeneratives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780040135.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1994/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007318059

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007853026

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007318059

Country of ref document: AU

Date of ref document: 20071030

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004627

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009535293

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2668162

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097011038

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009120573

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07853026

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0717874

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090430